The Clinical Conversation Is Shifting Toward Faster, Smarter Adjustments
A new analysis published in Psychiatric Times (April 2026) is drawing attention to how clinicians should be thinking about side effect management and discontinuation rates across the entire class of NMDA receptor antagonists — a drug family that includes IV ketamine, sublingual ketamine troches, intramuscular ketamine, and intranasal esketamine (Spravato). The authors make a pointed argument: too many patients are living too long with subtherapeutic doses or intolerable side effects before their providers make a meaningful change. The call to action is clear — optimize doses faster, switch delivery routes sooner when needed, and use standardized outcome tools like the PHQ-9 consistently to measure whether treatment is actually working.
For anyone currently using ketamine troches at home as part of a telepsychiatry protocol, this guidance lands differently than it does for infusion clinic patients. Troches occupy a unique space in the NMDA antagonist landscape: they're self-administered, absorbed transmucosally over 15–25 minutes, and offer a degree of flexibility that IV infusions and supervised esketamine sessions simply cannot match. That flexibility is a clinical asset — but the new data remind us it can also become a liability if dosing isn't being actively monitored and adjusted.
How Side Effect Profiles Actually Differ Across Delivery Routes
Not all ketamine treatments feel the same, and the Psychiatric Times review underscores why comparing side effect profiles across routes matters when a patient considers sticking with or discontinuing treatment. IV infusions deliver ketamine rapidly into systemic circulation, producing peak dissociative effects within minutes — effects that are intense, time-limited, and occur in a supervised clinical setting. Esketamine nasal spray (Spravato) works similarly: fast onset, supervised administration, a two-hour post-dose monitoring window.
Troches work differently at a physiological level. Sublingual and buccal absorption is slower and more variable than IV, and a meaningful portion of the dose is swallowed and undergoes first-pass hepatic metabolism, converting ketamine into norketamine — an active metabolite that contributes to the antidepressant effect without producing the same intensity of dissociation. This pharmacokinetic reality is why many troche users describe a gentler, more gradual onset compared to infusions. Blood plasma levels rise over 20–45 minutes rather than spiking within five.
The clinical implication is that troches tend to produce lower peak dissociation scores than IV ketamine at equivalent antidepressant doses, which is one reason discontinuation due to acute psychotomimetic effects — seeing things, feeling dangerously unmoored — is generally lower in troche-based protocols than in infusion reports. However, troches are not side-effect-free. Nausea, dizziness, transient blood pressure elevation, and oral numbness are common, especially early in treatment. The risk profile changes when patients self-administer without adequate preparation or push their dose higher than prescribed without clinical oversight.
Discontinuation Rates: What the Data Suggest and Why It Matters
Discontinuation is one of the least-discussed failure modes in ketamine therapy. Patients and providers focus heavily on whether ketamine will work — and understandably so — but the clinical literature increasingly points to a significant subset of patients who stop treatment not because it failed, but because side effects were never adequately managed. The Psychiatric Times authors argue this represents an avoidable treatment gap, particularly in treatment-resistant depression where every failed or abandoned trial delays remission and erodes patient confidence.
For troche-based protocols specifically, the discontinuation risk landscape looks like this: the most common early dropout reasons are GI intolerance (nausea that isn't pre-treated with an antiemetic), anxiety around the dissociative experience (especially in patients with trauma histories), and practical barriers like cost or insurance. Later discontinuation — after an initial response — often happens when patients plateau, when their dose hasn't been adjusted upward to maintain effect, or when they've never been given a clear maintenance protocol after their induction phase.
The PHQ-9 tracking emphasis in the new guidance is directly applicable here. Troche protocols that incorporate regular symptom scoring give providers a structured, objective basis for dose decisions. Without it, patients and clinicians are often navigating by intuition — and intuition tends to be conservative when it comes to dose escalation, even when escalation is clinically warranted. A patient who scores 14 on the PHQ-9 after four weeks of troches at 200mg is telling their provider something important that a subjective check-in might miss.
Key Takeaway for Troche Patients
If you've been on the same troche dose for more than four to six weeks without meaningful improvement in your depression symptoms, that's a signal worth raising with your prescriber — not a reason to quietly stop. The new clinical guidance explicitly supports faster dose optimization and route switching when a patient isn't responding. Staying at an ineffective dose out of caution isn't conservative care; it's a form of under-treatment. Ask your provider whether your PHQ-9 scores are being tracked, and if you're experiencing side effects that make dosing sessions dread-inducing rather than therapeutic, that conversation is overdue.
Practical Implications for Your Troche Routine
The guidance coming out of the psychiatric literature in 2026 points toward a more proactive, data-driven model of ketamine care — one that's especially achievable in troche-based telepsychiatry programs because the home-dosing format naturally lends itself to patient-reported tracking. Here's how to apply this thinking to your own protocol:
Track symptoms formally, not just casually. The PHQ-9 takes under two minutes to complete and gives your provider a number to work with. If your program doesn't already include regular scoring, ask to add it. Many telehealth platforms that prescribe troches now embed this into their check-in workflows.
Pre-treat side effects proactively. Nausea is one of the most common reasons patients under-dose or skip sessions. Ondansetron (Zofran) taken 30 minutes before your troche is a standard and effective antiemetic that won't blunt ketamine's antidepressant effect. If your protocol doesn't include a pre-treatment antiemetic option, raise it.
Don't self-adjust dose without clinical input — but don't stay stuck either. Troches are compounded to a specific dose, and the variability in home preparation and administration means that even small informal adjustments can have outsized effects. If your current dose isn't working or the side effects feel unmanageable, the right move is a provider conversation, not quiet self-experimentation. The clinical literature is now explicitly on your side in asking for that conversation sooner rather than later.
Understand the maintenance phase before you finish induction. A common failure point in troche protocols is a well-executed induction (typically six sessions over two to three weeks) followed by a poorly defined maintenance plan. Before you complete your induction, you should have a clear answer from your provider about frequency, dose, and what symptom threshold would trigger a return to more intensive dosing.
The full analysis is available at Psychiatric Times. For patients navigating ketamine troches as part of a treatment-resistant depression protocol, the central message is worth internalizing: side effects are manageable, dose optimization is appropriate, and discontinuing prematurely is a clinical outcome worth preventing.
Share